Serveur d'exploration sur les relations entre la France et l'Australie

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.

Identifieur interne : 000387 ( PubMed/Checkpoint ); précédent : 000386; suivant : 000388

Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.

Auteurs : Jean-Marc Steens [France] ; Didier Scherrer [France] ; Paul Gineste [Oman] ; P Noel Barrett [France] ; Supparatpino Khuanchai [Thaïlande] ; Ratanasuwan Winai [Thaïlande] ; Kiat Ruxrungtham [Thaïlande] ; Jamal Tazi [France] ; Robert Murphy [États-Unis] ; Hartmut Ehrlich [France]

Source :

RBID : pubmed:28507108

Abstract

We investigated the safety and antiviral effects of an anti-HIV compound (ABX464) with a unique mechanism of viral replication inhibition. This was a randomized, double-blind, placebo-controlled, dose-ranging study in treatment-naive HIV-infected patients. Participants were assigned to eight groups; each group included eight subjects receiving either the study compound, ABX464 (n = 6), or the corresponding placebo (n = 2), according to a randomization code. The first dose administered was 25 mg, given once or 3 times a day over a 2- to 3-week period. Ascending doses of up to 150 mg were delivered after review of the safety data. The primary objective of the study was to assess the safety and tolerability of ABX464 after repeated oral administrations in subjects infected by HIV. Sixty-six subjects were enrolled and were randomized. Sixty-three subjects completed the study according to the study protocol. Twenty-one adverse events (AEs) were reported by 7 subjects out of 16 (44%) who received placebo, and 158 AEs were reported by 39 subjects out of 50 (78%) who received the study drug. In the ABX464 treatment group, all of these adverse events were mild to moderate. No subjects discontinued treatment due to drug-related AEs. Administration of ABX464 at up to 150 mg once a day was safe and well tolerated in HIV-infected subjects. An efficacy signal with respect to a reduction of the viral load by ABX464 was detected, mainly in subjects treated at the highest dose. Further studies will be required to demonstrate antiviral effects in HIV-infected subjects in combination with other antiretroviral therapies. (This study is registered on the ClinicalTrials.gov website under registration no. NCT02452242.).

DOI: 10.1128/AAC.00545-17
PubMed: 28507108


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:28507108

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.</title>
<author>
<name sortKey="Steens, Jean Marc" sort="Steens, Jean Marc" uniqKey="Steens J" first="Jean-Marc" last="Steens">Jean-Marc Steens</name>
<affiliation wicri:level="3">
<nlm:affiliation>Abivax, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Abivax, Paris</wicri:regionArea>
<placeName>
<region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Scherrer, Didier" sort="Scherrer, Didier" uniqKey="Scherrer D" first="Didier" last="Scherrer">Didier Scherrer</name>
<affiliation wicri:level="3">
<nlm:affiliation>Abivax, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Abivax, Paris</wicri:regionArea>
<placeName>
<region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gineste, Paul" sort="Gineste, Paul" uniqKey="Gineste P" first="Paul" last="Gineste">Paul Gineste</name>
<affiliation wicri:level="3">
<nlm:affiliation>Abivax, Paris, France Paul.Gineste@abivax.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
<wicri:regionArea>Abivax, Paris</wicri:regionArea>
<placeName>
<settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name>
<affiliation wicri:level="3">
<nlm:affiliation>Independent Consultant, c/o Abivax, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Independent Consultant, c/o Abivax, Paris</wicri:regionArea>
<placeName>
<region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Khuanchai, Supparatpino" sort="Khuanchai, Supparatpino" uniqKey="Khuanchai S" first="Supparatpino" last="Khuanchai">Supparatpino Khuanchai</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Medicine, Chiang Mai University, Chiang Mai, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Medicine, Chiang Mai University, Chiang Mai</wicri:regionArea>
<wicri:noRegion>Chiang Mai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Winai, Ratanasuwan" sort="Winai, Ratanasuwan" uniqKey="Winai R" first="Ratanasuwan" last="Winai">Ratanasuwan Winai</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Preventive and Social Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Preventive and Social Medicine, Siriraj Hospital, Mahidol University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name>
<affiliation wicri:level="1">
<nlm:affiliation>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Chulalongkorn University Hospital, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Chulalongkorn University Hospital, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Tazi, Jamal" sort="Tazi, Jamal" uniqKey="Tazi J" first="Jamal" last="Tazi">Jamal Tazi</name>
<affiliation wicri:level="3">
<nlm:affiliation>Institut de Genetique Moleculaire, University of Montpellier, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Genetique Moleculaire, University of Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Murphy, Robert" sort="Murphy, Robert" uniqKey="Murphy R" first="Robert" last="Murphy">Robert Murphy</name>
<affiliation wicri:level="2">
<nlm:affiliation>Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Northwestern University Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName>
<region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Ehrlich, Hartmut" sort="Ehrlich, Hartmut" uniqKey="Ehrlich H" first="Hartmut" last="Ehrlich">Hartmut Ehrlich</name>
<affiliation wicri:level="3">
<nlm:affiliation>Abivax, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Abivax, Paris</wicri:regionArea>
<placeName>
<region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28507108</idno>
<idno type="pmid">28507108</idno>
<idno type="doi">10.1128/AAC.00545-17</idno>
<idno type="wicri:Area/PubMed/Corpus">000B33</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B33</idno>
<idno type="wicri:Area/PubMed/Curation">000B30</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B30</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B30</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B30</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.</title>
<author>
<name sortKey="Steens, Jean Marc" sort="Steens, Jean Marc" uniqKey="Steens J" first="Jean-Marc" last="Steens">Jean-Marc Steens</name>
<affiliation wicri:level="3">
<nlm:affiliation>Abivax, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Abivax, Paris</wicri:regionArea>
<placeName>
<region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Scherrer, Didier" sort="Scherrer, Didier" uniqKey="Scherrer D" first="Didier" last="Scherrer">Didier Scherrer</name>
<affiliation wicri:level="3">
<nlm:affiliation>Abivax, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Abivax, Paris</wicri:regionArea>
<placeName>
<region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gineste, Paul" sort="Gineste, Paul" uniqKey="Gineste P" first="Paul" last="Gineste">Paul Gineste</name>
<affiliation wicri:level="3">
<nlm:affiliation>Abivax, Paris, France Paul.Gineste@abivax.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
<wicri:regionArea>Abivax, Paris</wicri:regionArea>
<placeName>
<settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name>
<affiliation wicri:level="3">
<nlm:affiliation>Independent Consultant, c/o Abivax, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Independent Consultant, c/o Abivax, Paris</wicri:regionArea>
<placeName>
<region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Khuanchai, Supparatpino" sort="Khuanchai, Supparatpino" uniqKey="Khuanchai S" first="Supparatpino" last="Khuanchai">Supparatpino Khuanchai</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Medicine, Chiang Mai University, Chiang Mai, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Medicine, Chiang Mai University, Chiang Mai</wicri:regionArea>
<wicri:noRegion>Chiang Mai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Winai, Ratanasuwan" sort="Winai, Ratanasuwan" uniqKey="Winai R" first="Ratanasuwan" last="Winai">Ratanasuwan Winai</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Preventive and Social Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Preventive and Social Medicine, Siriraj Hospital, Mahidol University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name>
<affiliation wicri:level="1">
<nlm:affiliation>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Chulalongkorn University Hospital, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Chulalongkorn University Hospital, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Tazi, Jamal" sort="Tazi, Jamal" uniqKey="Tazi J" first="Jamal" last="Tazi">Jamal Tazi</name>
<affiliation wicri:level="3">
<nlm:affiliation>Institut de Genetique Moleculaire, University of Montpellier, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Genetique Moleculaire, University of Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Murphy, Robert" sort="Murphy, Robert" uniqKey="Murphy R" first="Robert" last="Murphy">Robert Murphy</name>
<affiliation wicri:level="2">
<nlm:affiliation>Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Northwestern University Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea>
<placeName>
<region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Ehrlich, Hartmut" sort="Ehrlich, Hartmut" uniqKey="Ehrlich H" first="Hartmut" last="Ehrlich">Hartmut Ehrlich</name>
<affiliation wicri:level="3">
<nlm:affiliation>Abivax, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Abivax, Paris</wicri:regionArea>
<placeName>
<region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Antimicrobial agents and chemotherapy</title>
<idno type="eISSN">1098-6596</idno>
<imprint>
<date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">We investigated the safety and antiviral effects of an anti-HIV compound (ABX464) with a unique mechanism of viral replication inhibition. This was a randomized, double-blind, placebo-controlled, dose-ranging study in treatment-naive HIV-infected patients. Participants were assigned to eight groups; each group included eight subjects receiving either the study compound, ABX464 (n = 6), or the corresponding placebo (n = 2), according to a randomization code. The first dose administered was 25 mg, given once or 3 times a day over a 2- to 3-week period. Ascending doses of up to 150 mg were delivered after review of the safety data. The primary objective of the study was to assess the safety and tolerability of ABX464 after repeated oral administrations in subjects infected by HIV. Sixty-six subjects were enrolled and were randomized. Sixty-three subjects completed the study according to the study protocol. Twenty-one adverse events (AEs) were reported by 7 subjects out of 16 (44%) who received placebo, and 158 AEs were reported by 39 subjects out of 50 (78%) who received the study drug. In the ABX464 treatment group, all of these adverse events were mild to moderate. No subjects discontinued treatment due to drug-related AEs. Administration of ABX464 at up to 150 mg once a day was safe and well tolerated in HIV-infected subjects. An efficacy signal with respect to a reduction of the viral load by ABX464 was detected, mainly in subjects treated at the highest dose. Further studies will be required to demonstrate antiviral effects in HIV-infected subjects in combination with other antiretroviral therapies. (This study is registered on the ClinicalTrials.gov website under registration no. NCT02452242.).</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="In-Process" Owner="NLM">
<PMID Version="1">28507108</PMID>
<DateCreated>
<Year>2017</Year>
<Month>05</Month>
<Day>16</Day>
</DateCreated>
<DateRevised>
<Year>2017</Year>
<Month>09</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Electronic-Print">
<Journal>
<ISSN IssnType="Electronic">1098-6596</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>61</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2017</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Antimicrobial agents and chemotherapy</Title>
<ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
</Journal>
<ArticleTitle>Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">e00545-17</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.00545-17</ELocationID>
<Abstract>
<AbstractText>We investigated the safety and antiviral effects of an anti-HIV compound (ABX464) with a unique mechanism of viral replication inhibition. This was a randomized, double-blind, placebo-controlled, dose-ranging study in treatment-naive HIV-infected patients. Participants were assigned to eight groups; each group included eight subjects receiving either the study compound, ABX464 (n = 6), or the corresponding placebo (n = 2), according to a randomization code. The first dose administered was 25 mg, given once or 3 times a day over a 2- to 3-week period. Ascending doses of up to 150 mg were delivered after review of the safety data. The primary objective of the study was to assess the safety and tolerability of ABX464 after repeated oral administrations in subjects infected by HIV. Sixty-six subjects were enrolled and were randomized. Sixty-three subjects completed the study according to the study protocol. Twenty-one adverse events (AEs) were reported by 7 subjects out of 16 (44%) who received placebo, and 158 AEs were reported by 39 subjects out of 50 (78%) who received the study drug. In the ABX464 treatment group, all of these adverse events were mild to moderate. No subjects discontinued treatment due to drug-related AEs. Administration of ABX464 at up to 150 mg once a day was safe and well tolerated in HIV-infected subjects. An efficacy signal with respect to a reduction of the viral load by ABX464 was detected, mainly in subjects treated at the highest dose. Further studies will be required to demonstrate antiviral effects in HIV-infected subjects in combination with other antiretroviral therapies. (This study is registered on the ClinicalTrials.gov website under registration no. NCT02452242.).</AbstractText>
<CopyrightInformation>Copyright © 2017 Steens et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Steens</LastName>
<ForeName>Jean-Marc</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Abivax, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Scherrer</LastName>
<ForeName>Didier</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Abivax, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gineste</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Abivax, Paris, France Paul.Gineste@abivax.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Barrett</LastName>
<ForeName>P Noel</ForeName>
<Initials>PN</Initials>
<AffiliationInfo>
<Affiliation>Independent Consultant, c/o Abivax, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Khuanchai</LastName>
<ForeName>Supparatpino</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Winai</LastName>
<ForeName>Ratanasuwan</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Preventive and Social Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ruxrungtham</LastName>
<ForeName>Kiat</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Chulalongkorn University Hospital, Bangkok, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tazi</LastName>
<ForeName>Jamal</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Institut de Genetique Moleculaire, University of Montpellier, Montpellier, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Murphy</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ehrlich</LastName>
<ForeName>Hartmut</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Abivax, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2017</Year>
<Month>06</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Antimicrob Agents Chemother</MedlineTA>
<NlmUniqueID>0315061</NlmUniqueID>
<ISSNLinking>0066-4804</ISSNLinking>
</MedlineJournalInfo>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Drug Discov Today. 2013 Jun;18(11-12):541-51</RefSource>
<PMID Version="1">23270785</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Genet. 2013 Apr;14(4):275-87</RefSource>
<PMID Version="1">23478349</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nucleic Acids Res. 2014 Jun;42(10):6645-58</RefSource>
<PMID Version="1">24753416</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Antimicrob Chemother. 2016 Mar;71(3):731-8</RefSource>
<PMID Version="1">26620101</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Virol. 2016 Jun;18:50-6</RefSource>
<PMID Version="1">27023283</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AIDS. 2010 Nov 27;24(18):2803-8</RefSource>
<PMID Version="1">20962613</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Bioessays. 2013 Jun;35(6):544-52</RefSource>
<PMID Version="1">23613347</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Immunol. 2015 Jun;16(6):584-9</RefSource>
<PMID Version="1">25990814</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J AIDS Clin Res. 2015 Nov 30;6:</RefSource>
<PMID Version="1">27774350</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Retrovirology. 2015 Apr 09;12:30</RefSource>
<PMID Version="1">25889234</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>FEBS J. 2010 Feb;277(4):867-76</RefSource>
<PMID Version="1">20082634</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Antimicrob Agents Chemother. 2016 Dec 27;61(1):</RefSource>
<PMID Version="1">27799203</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Int AIDS Soc. 2011 Jan 24;14:4</RefSource>
<PMID Version="1">21255462</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Antimicrob Chemother. 2017 Mar 1;72 (3):820-828</RefSource>
<PMID Version="1">27999038</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin HIV AIDS. 2016 Jul;11(4):383-7</RefSource>
<PMID Version="1">27023286</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin Infect Dis. 2013 Feb;26(1):17-25</RefSource>
<PMID Version="1">23221765</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Curr Opin HIV AIDS. 2016 Jul;11(4):362-70</RefSource>
<PMID Version="1">27259045</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Microbiol. 2014 Nov;12(11):750-64</RefSource>
<PMID Version="1">25402363</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Sci Rep. 2017 Jul 7;7(1):4860</RefSource>
<PMID Version="1">28687795</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nat Rev Microbiol. 2016 Jan;14 (1):55-60</RefSource>
<PMID Version="1">26616417</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AIDS Res Ther. 2016 Feb 08;13:7</RefSource>
<PMID Version="1">26858771</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">ABX464</Keyword>
<Keyword MajorTopicYN="N">human immunodeficiency virus</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2017</Year>
<Month>03</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2017</Year>
<Month>05</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2017</Year>
<Month>5</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>5</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2017</Year>
<Month>5</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">28507108</ArticleId>
<ArticleId IdType="pii">AAC.00545-17</ArticleId>
<ArticleId IdType="doi">10.1128/AAC.00545-17</ArticleId>
<ArticleId IdType="pmc">PMC5487684</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>France</li>
<li>Oman</li>
<li>Thaïlande</li>
<li>États-Unis</li>
</country>
<region>
<li>Illinois</li>
<li>Languedoc-Roussillon</li>
<li>Occitanie (région administrative)</li>
<li>Île-de-France</li>
</region>
<settlement>
<li>Montpellier</li>
<li>Paris</li>
</settlement>
</list>
<tree>
<country name="France">
<region name="Île-de-France">
<name sortKey="Steens, Jean Marc" sort="Steens, Jean Marc" uniqKey="Steens J" first="Jean-Marc" last="Steens">Jean-Marc Steens</name>
</region>
<name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name>
<name sortKey="Ehrlich, Hartmut" sort="Ehrlich, Hartmut" uniqKey="Ehrlich H" first="Hartmut" last="Ehrlich">Hartmut Ehrlich</name>
<name sortKey="Scherrer, Didier" sort="Scherrer, Didier" uniqKey="Scherrer D" first="Didier" last="Scherrer">Didier Scherrer</name>
<name sortKey="Tazi, Jamal" sort="Tazi, Jamal" uniqKey="Tazi J" first="Jamal" last="Tazi">Jamal Tazi</name>
</country>
<country name="Oman">
<region name="Île-de-France">
<name sortKey="Gineste, Paul" sort="Gineste, Paul" uniqKey="Gineste P" first="Paul" last="Gineste">Paul Gineste</name>
</region>
</country>
<country name="Thaïlande">
<noRegion>
<name sortKey="Khuanchai, Supparatpino" sort="Khuanchai, Supparatpino" uniqKey="Khuanchai S" first="Supparatpino" last="Khuanchai">Supparatpino Khuanchai</name>
</noRegion>
<name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name>
<name sortKey="Winai, Ratanasuwan" sort="Winai, Ratanasuwan" uniqKey="Winai R" first="Ratanasuwan" last="Winai">Ratanasuwan Winai</name>
</country>
<country name="États-Unis">
<region name="Illinois">
<name sortKey="Murphy, Robert" sort="Murphy, Robert" uniqKey="Murphy R" first="Robert" last="Murphy">Robert Murphy</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000387 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000387 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:28507108
   |texte=   Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:28507108" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024